Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BioNIR Ridaforolimus Eluting Coronary Stent System (BioNIR) In Coronary Stenosis Trial

Trial Profile

BioNIR Ridaforolimus Eluting Coronary Stent System (BioNIR) In Coronary Stenosis Trial

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Sep 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ridaforolimus (Primary) ; Zotarolimus
  • Indications Coronary artery restenosis
  • Focus Therapeutic Use
  • Acronyms BIONICS
  • Sponsors Medinol
  • Most Recent Events

    • 25 Sep 2018 Results assessing 2-year clinical outcomes of the pooled BIONICS and NIREUS Trials presented at the 30th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics
    • 25 Sep 2018 One-year outcome results Ridaforolimus-Eluting and Zotarolimus-Eluting Coronary Stents in Patients with Long Lesions, presented at the 30th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics
    • 09 Aug 2017 Primary results of BIONICS study comparing safety and efficacy, published in the Circulation.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top